Jen­do – Heart Dis­ease Pre­dic­tion using Machine Learn­ing

Jen­do – A 15‑Minute AI‑Powered Heart Check

🩺 Jendo’s 15‑Minute Heart‑Health Screen­ing

1. Prepa­ra­tion & Set­up
   • A sen­sor is placed on the patient’s thumb fea­tur­ing red and infrared light emit­ters. WIPO+4WIPO+4nia.gov.lk+4
2. 5‑Minute Occlu­sion Test
   • Blood flow is tem­porar­i­ly stopped via a cuff or sim­i­lar device for five min­utes, sim­u­lat­ing stress on the endothe­li­um. WIPO
3. Release & Data Record­ing
   • After releas­ing the cuff, pulse and tem­per­a­ture sig­nals are cap­tured by the sen­sor, reflect­ing how the blood ves­sels respond. WIPO
4. Machine‑Learning Analy­sis
   • These sig­nals feed into a com­plex ML algo­rithm that has been trained to rec­og­nize pat­terns linked to endothe­lial dys­func­tion, the ear­li­est stage of vas­cu­lar dis­ease. WIPO
5. Risk Pre­dic­tion Report
   • The sys­tem out­puts a risk pre­dic­tion for car­dio­vas­cu­lar issues (and poten­tial­ly dia­betes or kid­ney dis­ease), and gen­er­ates a report with per­son­al­ized lifestyle advice.
6. Rec­om­mend­ed Envi­ron­ment
   • Designed to be used under med­ical super­vi­sion, ide­al­ly at facil­i­ties. Home use is pos­si­ble if instruc­tions are strict­ly fol­lowed. WIPO

---

🌟 Clin­i­cal Use & Busi­ness Con­text

• Scale of test­ing: Clin­i­cal­ly val­i­dat­ed on over 800 patients and cur­rent­ly in use at hos­pi­tals and labs, though it’s not yet com­mer­cial­ized. WIPO
• Pric­ing mod­el: The device is planned to retail at US $2,250, with an annu­al sub­scrip­tion of US $10,000, and a per‑test cost of US $8 — mak­ing it a cost‑effective alter­na­tive to tra­di­tion­al diag­nos­tics. WIPO

---

🚀 Inno­va­tion & Expan­sion Strat­e­gy

Growth plans: Explor­ing busi­ness set­up in Switzer­land and Sin­ga­pore to scale inter­na­tion­al­ly.

Patent pro­tec­tion:

Sri Lan­ka: Pend­ing

Unit­ed States: Grant­ed (USPTO 10,912,464 B2)

Japan: PCT appli­ca­tion pend­ing bayareaeconomy.org+2WIPO+2keerthikodithuwakku.com+2

Reg­u­la­to­ry roadmap: Under­go­ing review by Sri Lanka’s med­ical reg­u­la­tor, with future plans for FDA approval (USA) and sub­mis­sions in oth­er juris­dic­tions.